Company Name
Jiangsu Simcere Pharmaceutical Co., Ltd.
Year of Establishment
1995-03-28
Enterprise Size
more than 500
Annual Turnover(USD)
choose not to disclose
Company Introduction
Jiangsu Simcere Pharmaceutical Co., Ltd was founded on March 28, 1995 with an enterprise mission to "discover and develop high-quality medicines for patients. " Since its inception, we have grown from a registered capital of 2.78 million to total assets of over 3 billion yuan, from a few dozen people to a R&D-driven pharmaceutical enterprise with more than 3, 000 talents, and from an annual tax of less than a million to about 500 million yuan. We have ranked among "the top 100 Chinese Pharmaceutical Companies" for consecutive years, and our growth goes beyond the numbers.
To fulfill our dream, we have progressed through a string of strategic options, including but not limited to the development of first generic products, merger and acquisition, the build-up of research institute, an alliance with multinational corporations, and innovative research mechanisms.
At present, these efforts are bearing fruits: In 2009, our montmorillonite powder product successfully passed EU GMP certification and started exporting to Europe, a milestone for 'Made in Simcere' for global markets. Currently, we are actively implementing cGMP and EUGMP to transform all of our small molecule manufacture sites to comply with international standards.
In recent years, Simcere has established high-quality international cooperation through various partnership models. For example, we partnered with American Apexigen Company to develop an innovative anti-VEGF humanized monoclonal antibody in China. Together with Bristol-Myers Squibb, we are conducting Phase III trial for abatacept, a monoclonal antibody for treatment of rheumatoid arthritis, and so forth. These partnerships are a powerful testament to the fact that Chinese pharmaceutical companies can collaborate with multinational corporations to scale down R&D cost and accelerate R&D innovation in China. The Ministry of Science and Technology recognized our Company as an 'International Scientific and Technological Cooperation Base.
We now own over 50 products that cover Oncology, Cardiovascular and Cerebrovascular, Anti-infection, Rheumatology and other therapeutic areas. We have three products (Endostar® , Sinofuan® , Iremod® ) that were the first-to-launch in the world, and six products (BICUN® , ZAILIN® , ANTINE® , YEQING® , JIEBAISHU® , Newanti® ) that were the first-in-class in China. Since 2007, we have submitted over 200 domestic and PCT patent applications. Over 10 innovative drugs are being studied in clinical trials, which will broaden our current marketed product portfolio.
In 2015, the Ministry of Science and Technology designated one of our laboratories as the 'national key laboratory for translational medicine and innovative drugs'. Simcere ranks among the 'Top 10 Chinese Companies in Pharmaceutical Innovation' in recent years.
Main Competitive Advantages
Brandname,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production capacity,Large Product Line,Contract Manufacturing,Reputation,Quality Service,
Website
http://www.simcere.com/
Other Competitive Advantages
Milestone
2017
Strategic allicance between Amgen and Simcere for co-development and co-commercialization of biosimilars in China.
2016
Enable some production of affiliates of relocation, the expansion of the work And the raw materials and preparations of Hainan simcere get the EU cGMP certification again.
2015
The strategic cooperation agreement with Daiichi Sankyo Co. Ltd. was concluded, for jointly forming hypertension compound brand - OLMETEC®
2014
The entrepreneurial community -“BioSciKin”was put into use
2013
Orencia of BMS used for rheumatoid arthritis was developed and commercialized with BMS in China
2012
The State Category1.1 New Drug- Iremod®(Iguratimod Tablets) researched and developed independently was listed
2011
Simcere pharmaceutical R&D lab covering 26000 ㎡ has been totally put into use,and EU GMP certificate for Montmorillonite PowderPreparation( Biqi®) was passed
2010
The EU GMP certificate for active ingredient of Biqi(Montmorillonite Powder) - Montmorillonite raw material was passed, and the certificate was obtained;
With BMS announced a strategic cooperative relations, and develop antitumor drugs BMS - 817378
2009
Agreement between Simcere and other famous companies such as American Epitomics, OSI, etc. was concluded, in order to develop many international innovative drugs jointly
2008
The domestic firstly listed brand medicines such as Sinofuan®(Fluorouracil Implants) ,Jiebaishu®(Nedaplatin for Injection), Newanti® (Biapenem for Injection), etc. were successively launched, and the enterprise development strategy was further carried out
2007
Simcere entered the largest capital market in the world-NYSE, with the stock code “SCR”
2006
Simcere merged 80% of share of Yantai Medgenn Co., Ltd., and the State Category Ⅰ New Drug of antineoplastic - ENDOSTAR was officially listed, entering field of tumor treatment
2005
HONY CAPITAL under Legend holdings was introduced as strategic investor
2004
BICUN®(Edaravone Injection) was successfully researched and developed firstly throughout the country and secondly in the world
2003
Simcere Group and Simcere Drug Research Institute were officially formed
2000
Simcere New Drugs Research Center was founded, and firstly started R&D of BICUN®(Edaravone Injection) domestically
1999
Jiangsu Cuccess Pharma. was renamed as Simcere
1996-98
Jiangsu Cuccess suffered from many setbacks such as disincorporation of enterpreneur team, termination of general dealership requested by partners, etc
1995
Jiangsu Cuccess Pharmaceutical Co., Ltd. was established, and initially created mode of “General Agency”in the industry